432 related articles for article (PubMed ID: 24511610)
21. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
22. Encapsulation of lipophilic kiteplatin Pt(iv) prodrugs in PLGA-PEG micelles.
Margiotta N; Savino S; Denora N; Marzano C; Laquintana V; Cutrignelli A; Hoeschele JD; Gandin V; Natile G
Dalton Trans; 2016 Aug; 45(33):13070-81. PubMed ID: 27094010
[TBL] [Abstract][Full Text] [Related]
23. Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug.
Ravera M; Gabano E; Bonzani D; Zanellato I; Arrais A; Cantamessa S; Biggiogera M; Osella D
J Inorg Biochem; 2018 Dec; 189():185-191. PubMed ID: 30312905
[TBL] [Abstract][Full Text] [Related]
24. The Platin-X series: activation, targeting, and delivery.
Basu U; Banik B; Wen R; Pathak RK; Dhar S
Dalton Trans; 2016 Aug; 45(33):12992-3004. PubMed ID: 27493131
[TBL] [Abstract][Full Text] [Related]
25. Emerging JWA-targeted Pt(IV) prodrugs conjugated with CX-4945 to overcome chemo-immune-resistance.
Chen F; Pei S; Wang X; Zhu Q; Gou S
Biochem Biophys Res Commun; 2020 Jan; 521(3):753-761. PubMed ID: 31703842
[TBL] [Abstract][Full Text] [Related]
26. Nanoparticle delivery of photosensitive Pt(IV) drugs for circumventing cisplatin cellular pathway and on-demand drug release.
Du R; Xiao H; Guo G; Jiang B; Yan X; Li W; Yang X; Zhang Y; Li Y; Jing X
Colloids Surf B Biointerfaces; 2014 Nov; 123():734-41. PubMed ID: 25454669
[TBL] [Abstract][Full Text] [Related]
27. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug.
Lee KGZ; Babak MV; Weiss A; Dyson PJ; Nowak-Sliwinska P; Montagner D; Ang WH
ChemMedChem; 2018 Jun; 13(12):1210-1217. PubMed ID: 29637702
[TBL] [Abstract][Full Text] [Related]
28. New NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo.
Song XQ; Ma ZY; Wu YG; Dai ML; Wang DB; Xu JY; Liu Y
Eur J Med Chem; 2019 Apr; 167():377-387. PubMed ID: 30784875
[TBL] [Abstract][Full Text] [Related]
29. Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity.
Barnes JC; Bruno PM; Nguyen HV; Liao L; Liu J; Hemann MT; Johnson JA
J Am Chem Soc; 2016 Sep; 138(38):12494-501. PubMed ID: 27626288
[TBL] [Abstract][Full Text] [Related]
30. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
31. Platinum(IV) Prodrugs.
Venkatesh V; Sadler PJ
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394022
[TBL] [Abstract][Full Text] [Related]
32. Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance.
Ling X; Chen X; Riddell IA; Tao W; Wang J; Hollett G; Lippard SJ; Farokhzad OC; Shi J; Wu J
Nano Lett; 2018 Jul; 18(7):4618-4625. PubMed ID: 29902013
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and Characterization of Nitric Oxide-Releasing Platinum(IV) Prodrug and Polymeric Micelle Triggered by Light.
Pramanick S; Kim J; Kim J; Saravanakumar G; Park D; Kim WJ
Bioconjug Chem; 2018 Apr; 29(4):885-897. PubMed ID: 29281788
[TBL] [Abstract][Full Text] [Related]
34. Human transport protein carrier for controlled photoactivation of antitumor prodrug and real-time intracellular tumor imaging.
Li X; Mu J; Liu F; Tan EW; Khezri B; Webster RD; Yeow EK; Xing B
Bioconjug Chem; 2015 May; 26(5):955-61. PubMed ID: 25938732
[TBL] [Abstract][Full Text] [Related]
35. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.
Johnstone TC; Suntharalingam K; Lippard SJ
Chem Rev; 2016 Mar; 116(5):3436-86. PubMed ID: 26865551
[TBL] [Abstract][Full Text] [Related]
36. Reprogramming axial ligands facilitates the self-assembly of a platinum(iv) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin.
Fang T; Ye Z; Wu J; Wang H
Chem Commun (Camb); 2018 Aug; 54(66):9167-9170. PubMed ID: 30062328
[TBL] [Abstract][Full Text] [Related]
37. Biodegradable polymer - cisplatin(IV) conjugate as a pro-drug of cisplatin(II).
Xiao H; Qi R; Liu S; Hu X; Duan T; Zheng Y; Huang Y; Jing X
Biomaterials; 2011 Oct; 32(30):7732-9. PubMed ID: 21783244
[TBL] [Abstract][Full Text] [Related]
38. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles.
Min Y; Li J; Liu F; Yeow EK; Xing B
Angew Chem Int Ed Engl; 2014 Jan; 53(4):1012-6. PubMed ID: 24311528
[TBL] [Abstract][Full Text] [Related]
39. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
[TBL] [Abstract][Full Text] [Related]
40. Near infrared activation of an anticancer Pt(IV) complex by Tm-doped upconversion nanoparticles.
Ruggiero E; Hernández-Gil J; Mareque-Rivas JC; Salassa L
Chem Commun (Camb); 2015 Feb; 51(11):2091-4. PubMed ID: 25536114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
